Councilman’s campaign goes high-tech
Raleigh City Councilman Bonner Gaylord wants supporters of his reelection bid to help him out on social media websites.
Gaylord’s campaign has launched a “Social Media Ambassador” program, which he says is the first of its kind. Supporters are asked to visit his website and sign up for email links to campaign information with instructions to share them through social media platforms.
“Conversations on social media have a large impact on public debate,” Gaylord wrote in an email to supporters. “We want to keep the campaign conversations positive, so I hope you will consider joining our group of Social Media Ambassadors. as we coordinate our efforts we will help shape the debate and keep Raleigh moving forward.”
Never miss a local story.
It’s not the councilman’s only high-tech initiative. He’s also launching a program called Raleigh+ Discussions, where he’ll host regular meetings with constituents through the video chat service Google+ Hangouts.
“We’ll be discussing Raleigh issues ranging from public safety to mental health, from small business development to university connections,” Gaylord writes on his campaign website.
Gaylord, who is also the general manager of North Hills, is seeking another term in October. So far, he has no opponents. Staff writer Colin Campbell
Raleigh pharma tries again with ‘pink Viagra’
Raleigh-based Sprout Pharmaceuticals is trying again to help premenopausal women get in the mood.
The company confirmed Wednesday that it submitted the drug flibanserin for Food and Drug Administration review earlier this year. Flibanserin, originally developed as an antidepressant, is now being evaluated as a treatment for Hypo-Active Sexual Desire Disorder in premenopausal women. This is second time that the drug has been submitted to the FDA as a treatment for HSDD.
HSDD is defined as a recurrent deficiency of sexual thoughts or desire for sexual activity. The condition may affect about 10 percent of premenopausal women in the United States, according to a recent medical study published in the Journal of Sexual Medicine.
Boehringer Ingelheim was the first pharmaceutical company to submit flibanserin, sometimes referred to as “pink Viagra,” for evaluation as a treatment for HSDD. The FDA voted against the drug’s approval in 2010 after concluding that flibanserin did not treat HSDD significantly better than a placebo, and that the drug’s benefits did not outweigh its adverse effects, which included drowsiness, nausea and dizziness.
The FDA is expected to respond to the new drug application this year. Staff writer Katherine Blunt